These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26761396)

  • 1. Effects of modification of the HIV-1 Env cytoplasmic tail on immunogenicity of VLP vaccines.
    Vzorov AN; Wang L; Chen J; Wang BZ; Compans RW
    Virology; 2016 Feb; 489():141-50. PubMed ID: 26761396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting.
    Cheng C; Xu K; Kong R; Chuang GY; Corrigan AR; Geng H; Hill KR; Jafari AJ; O'Dell S; Ou L; Rawi R; Rowshan AP; Sarfo EK; Sastry M; Saunders KO; Schmidt SD; Wang S; Wu W; Zhang B; Doria-Rose NA; Haynes BF; Scorpio DG; Shapiro L; Mascola JR; Kwong PD
    PLoS One; 2019; 14(4):e0215163. PubMed ID: 30995238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
    Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
    J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
    Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
    J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A novel immunization strategy to induce strong humoral responses against HIV-1 using combined DNA, recombinant vaccinia virus and protein vaccines].
    Liu C; Wang SH; Ren L; Hao YL; Zhang QC; Liu Y
    Bing Du Xue Bao; 2014 Nov; 30(6):645-51. PubMed ID: 25868279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines.
    Elsayed H; Nabi G; McKinstry WJ; Khoo KK; Mak J; Salazar AM; Tenbusch M; Temchura V; Überla K
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29743369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.
    Chuang GY; Lai YT; Boyington JC; Cheng C; Geng H; Narpala S; Rawi R; Schmidt SD; Tsybovsky Y; Verardi R; Xu K; Yang Y; Zhang B; Chambers M; Changela A; Corrigan AR; Kong R; Olia AS; Ou L; Sarfo EK; Wang S; Wu W; Doria-Rose NA; McDermott AB; Mascola JR; Kwong PD
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.
    Bontjer I; Melchers M; Tong T; van Montfort T; Eggink D; Montefiori D; Olson WC; Moore JP; Binley JM; Berkhout B; Sanders RW
    PLoS One; 2013; 8(6):e67484. PubMed ID: 23840716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.
    Quan FS; Sailaja G; Skountzou I; Huang C; Vzorov A; Compans RW; Kang SM
    Vaccine; 2007 May; 25(19):3841-50. PubMed ID: 17320250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrastructural help: improving the HIV-1 envelope antibody response induced by virus-like particle vaccines.
    Temchura V; Überla K
    Curr Opin HIV AIDS; 2017 May; 12(3):272-277. PubMed ID: 28422791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [VLP vaccines and effects of HIV-1 Env protein modifications on their antigenic properties].
    Vzorov AN; Compans RW
    Mol Biol (Mosk); 2016; 50(3):406-15. PubMed ID: 27414779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.
    Visciano ML; Diomede L; Tagliamonte M; Tornesello ML; Asti V; Bomsel M; Buonaguro FM; Lopalco L; Buonaguro L
    Vaccine; 2011 Jul; 29(31):4903-12. PubMed ID: 21596074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.
    Medina-Ramírez M; Sanders RW; Sattentau QJ
    Curr Opin HIV AIDS; 2017 May; 12(3):241-249. PubMed ID: 28422788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence.
    Nadai Y; Held K; Joseph S; Ahmed MIM; Hoffmann VS; Peterhoff D; Missanga M; Bauer A; Joachim A; Reimer U; Zerweck J; McCormack S; Cope AV; Tatoud R; Shattock RJ; Robb ML; Sandstroem EG; Hoelscher M; Maboko L; Bakari M; Kroidl A; Wagner R; Weber J; Pollakis G; Geldmacher C
    Front Immunol; 2019; 10():717. PubMed ID: 31105688
    [No Abstract]   [Full Text] [Related]  

  • 16. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
    J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
    Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.
    Tong T; Crooks ET; Osawa K; Binley JM
    J Virol; 2012 Apr; 86(7):3574-87. PubMed ID: 22301141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.
    Sarkar S; Piepenbrink MS; Basu M; Thakar J; Keefer MC; Hessell AJ; Haigwood NL; Kobie JJ
    Vaccine; 2019 Apr; 37(17):2322-2330. PubMed ID: 30926296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination].
    Vzorov AN; Uryvaev LV
    Mol Biol (Mosk); 2017; 51(6):945-957. PubMed ID: 29271959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.